BRPI0819932A2 - composição, uso de uma composição, dispositivo nebulizador, inalador ou intranasal, processos para produzir uma composição farmacêutica e uma composição polipeptídica, e, uso de um tampão fisiologicamente aceitável. - Google Patents
composição, uso de uma composição, dispositivo nebulizador, inalador ou intranasal, processos para produzir uma composição farmacêutica e uma composição polipeptídica, e, uso de um tampão fisiologicamente aceitável.Info
- Publication number
- BRPI0819932A2 BRPI0819932A2 BRPI0819932A BRPI0819932A BRPI0819932A2 BR PI0819932 A2 BRPI0819932 A2 BR PI0819932A2 BR PI0819932 A BRPI0819932 A BR PI0819932A BR PI0819932 A BRPI0819932 A BR PI0819932A BR PI0819932 A2 BRPI0819932 A2 BR PI0819932A2
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- nebulizer
- inhaler
- processes
- producing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
composição, uso de uma composição, dispositivo nebulizador, inalador ou intranasal, processos para produzir uma composição farmacêutica e uma composição polipeptídica, e, uso de um tampão fisiologicamente aceitável a presente invenção diz respeito a métodos de administração pulmonar direta de polipeptídeos, por exemplo, de anticorpos de domínio, e a composições polipeptídicas particulares adequadas para administração pulmonar direta. a invenção também diz respeito ao uso de tais composições na medicina, por exemplo, para o tratamento e diagnóstico de doença pulmonar, por exemplo, para tratar doença pulmonar obstrutiva crônica (copd) e asma.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0724331.4A GB0724331D0 (en) | 2007-12-13 | 2007-12-13 | Compositions for pulmonary delivery |
| BD1272008 | 2008-05-22 | ||
| BD1302008 | 2008-05-22 | ||
| BD1282008 | 2008-05-22 | ||
| BD1292008 | 2008-05-22 | ||
| PCT/GB2008/050399 WO2008149143A2 (en) | 2007-06-06 | 2008-06-03 | Methods for selecting protease resistant polypeptides |
| PCT/GB2008/050400 WO2008149144A2 (en) | 2007-06-06 | 2008-06-03 | Polypeptides, antibody variable domains and antagonists |
| PCT/GB2008/050403 WO2008149146A2 (en) | 2007-06-06 | 2008-06-03 | Polypeptides, antibody variable domains and antagonists |
| PCT/EP2008/067295 WO2009074634A2 (en) | 2007-12-13 | 2008-12-11 | Compositions for pulmonary delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0819932A2 true BRPI0819932A2 (pt) | 2019-07-30 |
Family
ID=61230984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0819932A BRPI0819932A2 (pt) | 2007-12-13 | 2008-12-11 | composição, uso de uma composição, dispositivo nebulizador, inalador ou intranasal, processos para produzir uma composição farmacêutica e uma composição polipeptídica, e, uso de um tampão fisiologicamente aceitável. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100260853A1 (pt) |
| EP (1) | EP2220115A2 (pt) |
| JP (1) | JP2011506396A (pt) |
| KR (1) | KR20100098697A (pt) |
| CN (1) | CN102131827A (pt) |
| AU (1) | AU2008334605B2 (pt) |
| BR (1) | BRPI0819932A2 (pt) |
| CA (1) | CA2707986A1 (pt) |
| EA (1) | EA201000785A1 (pt) |
| SG (1) | SG185286A1 (pt) |
| TW (1) | TW200938222A (pt) |
| WO (1) | WO2009074634A2 (pt) |
| ZA (1) | ZA201004093B (pt) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
| EP2301967A3 (en) | 2002-11-08 | 2011-07-13 | Ablynx N.V. | Single domain antibodies for nasal administration |
| US20060034845A1 (en) | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
| EP2386858B1 (en) | 2006-04-04 | 2015-07-15 | Singulex, Inc. | Highly sensitive system and methods for analysis of troponin |
| US7838250B1 (en) | 2006-04-04 | 2010-11-23 | Singulex, Inc. | Highly sensitive system and methods for analysis of troponin |
| NZ580530A (en) * | 2007-06-06 | 2012-04-27 | Domantis Ltd | Anti vegf polypeptides, antibody variable domains and antagonists |
| WO2010037818A1 (en) * | 2008-10-02 | 2010-04-08 | Ablynx Nv | Amino acid sequences directed against il-15 and/or the il-15 receptor and polypeptides comprising the same for the treatment of diseases and disorders associated with il-15 mediated signalling |
| KR20110092328A (ko) * | 2008-11-26 | 2011-08-17 | 글락소 그룹 리미티드 | Ｉｌ-13에 결합하는 리간드 |
| AU2010259022B2 (en) | 2009-06-08 | 2016-05-12 | Singulex, Inc. | Highly sensitive biomarker panels |
| MX2012003939A (es) * | 2009-09-30 | 2012-07-30 | Glaxo Group Ltd | Fusiones y conjugados de farmaco. |
| CA2787718C (en) | 2010-02-11 | 2018-05-15 | Ablynx Nv | Methods and compositions for the preparation of aerosols |
| TW201215405A (en) | 2010-08-25 | 2012-04-16 | Hoffmann La Roche | Antibodies against IL-18R1 and uses thereof |
| EP2635600B1 (en) * | 2010-11-05 | 2017-06-21 | F. Hoffmann-La Roche AG | Optimized method for antibody capturing by mixed mode chromatography |
| AU2011336470B8 (en) | 2010-12-01 | 2017-09-14 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| AU2012250872B2 (en) * | 2011-05-02 | 2017-07-13 | Millennium Pharmaceuticals, Inc. | Formulation for anti-alpha4beta7 antibody |
| WO2012163519A1 (en) * | 2011-05-27 | 2012-12-06 | Dutalys | Antibodies with improved folding stability |
| JP6292718B2 (ja) | 2011-07-01 | 2018-03-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 凝集ポリペプチドから単量体ポリペプチドを分離するための方法 |
| BR112014001855A2 (pt) * | 2011-07-27 | 2017-02-21 | Glaxo Group Ltd | construto e proteína aglutinantes ao antígeno, dímero, composição farmacêutica, sequência de polinucleotídeo, célula hospedeira e, método para produção do construto |
| ES2813432T3 (es) | 2011-08-17 | 2021-03-23 | Glaxo Group Ltd | Proteínas y péptidos modificados |
| AU2014233055B2 (en) | 2013-03-15 | 2018-08-09 | Board Of Regents, The University Of Texas System | Inhibition of pulmonary fibrosis with nutlin-3a and peptides |
| DK3125942T3 (da) * | 2014-04-03 | 2021-12-20 | Csl Behring Ag | Forstøvning af immunoglobulin |
| EP3198023B1 (en) | 2014-09-26 | 2020-04-22 | Somalogic, Inc. | Cardiovascular risk event prediction and uses thereof |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| JP6866296B2 (ja) * | 2015-02-27 | 2021-04-28 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | ポリペプチド治療及びその使用 |
| CN121159628A (zh) | 2018-09-10 | 2025-12-19 | 莱恩治疗公司 | Cav-1蛋白的修饰的肽片段及其在纤维化治疗中的用途 |
| US20220025019A1 (en) * | 2018-11-30 | 2022-01-27 | Csl Behring Ag | Methods and compositions for preventing or treating acute exacerbations with polyclonal immunoglobulin |
| JP2023512286A (ja) * | 2020-01-31 | 2023-03-24 | サノフイ | 抗体の肺送達 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4620670A (en) * | 1983-11-28 | 1986-11-04 | Vortran Corporation | Gas-powered nebulizer |
| FI960253A7 (fi) * | 1993-07-19 | 1996-03-18 | Amgen Inc | Aerosolisoitujen proteiinien stabilointi |
| US6165463A (en) * | 1997-10-16 | 2000-12-26 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| US7312196B2 (en) * | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US6858199B1 (en) * | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
| US6667344B2 (en) * | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| US20030064052A1 (en) * | 2001-05-21 | 2003-04-03 | Ponwell Enterprises, Ltd. | Compositions for protein delivery via the pulmonary route |
| EP2301967A3 (en) * | 2002-11-08 | 2011-07-13 | Ablynx N.V. | Single domain antibodies for nasal administration |
| ATE530165T1 (de) * | 2003-11-14 | 2011-11-15 | Baxter Int | Alpha1-antitrypsin-zusammensetzungen und behandlungsverfahren unter verwendung dieser zusammensetzungen |
| EP1694314A4 (en) * | 2003-12-04 | 2009-07-01 | Scripps Research Inst | TREATMENT AND PREVENTION OF ASTHMA |
| GB0405634D0 (en) * | 2004-03-12 | 2004-04-21 | Univ Southampton | Anti-virus therapy for respiratory diseases |
| GB0521621D0 (en) * | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
| EP1863847A2 (en) * | 2004-12-02 | 2007-12-12 | Domantis Limited | Anti-il-1r1 single domain antibodies and therapeutic uses |
| WO2006097521A1 (en) * | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Pegylated single-chain insulin |
| US20090324699A1 (en) * | 2005-09-01 | 2009-12-31 | Lena Preswetoff-Morath | Antihistamine-and corticosteroid-containing lipsome composition and its use for the manufacture of medicament for treating rhinitis and related disorders |
| JP2009517069A (ja) * | 2005-12-01 | 2009-04-30 | ドマンティス リミテッド | インターロイキン１受容体１型に結合する競合ドメイン抗体フォーマット |
| CA2632417A1 (en) * | 2005-12-06 | 2007-06-14 | Domantis Limited | Ligands that have binding specificity for egfr and/or vegf and methods of use therefor |
| WO2007082068A2 (en) * | 2006-01-11 | 2007-07-19 | Aerovance, Inc. | Methods and compositions for treating asthma in human and non human primates |
| AU2007209202A1 (en) * | 2006-01-24 | 2007-08-02 | Domantis Limited | Ligands that bind IL-4 and/or IL-13 |
| CA2688434A1 (en) * | 2007-06-06 | 2008-12-11 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
-
2008
- 2008-12-11 BR BRPI0819932A patent/BRPI0819932A2/pt not_active IP Right Cessation
- 2008-12-11 WO PCT/EP2008/067295 patent/WO2009074634A2/en not_active Ceased
- 2008-12-11 SG SG2012074878A patent/SG185286A1/en unknown
- 2008-12-11 EA EA201000785A patent/EA201000785A1/ru unknown
- 2008-12-11 TW TW097148298A patent/TW200938222A/zh unknown
- 2008-12-11 AU AU2008334605A patent/AU2008334605B2/en not_active Ceased
- 2008-12-11 EP EP08860520A patent/EP2220115A2/en not_active Withdrawn
- 2008-12-11 CN CN2008801271605A patent/CN102131827A/zh active Pending
- 2008-12-11 US US12/747,203 patent/US20100260853A1/en not_active Abandoned
- 2008-12-11 JP JP2010537443A patent/JP2011506396A/ja active Pending
- 2008-12-11 CA CA2707986A patent/CA2707986A1/en not_active Abandoned
- 2008-12-11 KR KR1020107015536A patent/KR20100098697A/ko not_active Ceased
-
2010
- 2010-06-08 ZA ZA2010/04093A patent/ZA201004093B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102131827A (zh) | 2011-07-20 |
| TW200938222A (en) | 2009-09-16 |
| CA2707986A1 (en) | 2009-06-18 |
| KR20100098697A (ko) | 2010-09-08 |
| EP2220115A2 (en) | 2010-08-25 |
| WO2009074634A2 (en) | 2009-06-18 |
| WO2009074634A3 (en) | 2010-09-23 |
| US20100260853A1 (en) | 2010-10-14 |
| AU2008334605B2 (en) | 2013-07-18 |
| JP2011506396A (ja) | 2011-03-03 |
| EA201000785A1 (ru) | 2011-02-28 |
| SG185286A1 (en) | 2012-11-29 |
| ZA201004093B (en) | 2011-11-30 |
| AU2008334605A1 (en) | 2009-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0819932A2 (pt) | composição, uso de uma composição, dispositivo nebulizador, inalador ou intranasal, processos para produzir uma composição farmacêutica e uma composição polipeptídica, e, uso de um tampão fisiologicamente aceitável. | |
| MY207466A (en) | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist | |
| EA200901495A1 (ru) | Полипептиды, вариабельные домены антител и антагонисты | |
| UY31686A1 (es) | Nueva dosificacion y formulacion | |
| AR067639A1 (es) | Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente | |
| WO2008149144A3 (en) | Polypeptides, antibody variable domains and antagonists | |
| BR112015006571A2 (pt) | composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para a profilaxia ou tratamento de asma, doença pulmonar obstrutiva crônica e distúrbios respiratórios relacionados | |
| WO2007092772A8 (en) | Protein formulations | |
| EA201190108A1 (ru) | Фармацевтическая композиция для ингаляции | |
| AR073528A1 (es) | Particulas inhalables que comprenden tiotropio | |
| UY31687A1 (es) | Nueva dosificacion y formulacion | |
| MX2011008799A (es) | Polipeptidos, dominios variables de anticuerpos, y antagonistas anti-tnfr1 mejorados. | |
| EA201201397A1 (ru) | Ингалятор, содержащий расслаиваемую блистерную упаковку | |
| CO6400235A2 (es) | Tensiactivos reconstituidos que tienen propiedades mejoradas | |
| MX2009008363A (es) | Combinacion de un antagonista de receptor muscarinico y un agonista de receptor adrenergico beta 2. | |
| PH12017502087A1 (en) | Tiotropium inhalation solution for nebulization | |
| PH12012500826A1 (en) | Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists | |
| EP2682097A3 (en) | Dry Powder Inhalers Comprising A Carrier Other Than Lactose | |
| EA201201392A1 (ru) | Кнопочное устройство мундштука ингалятора сухого порошка | |
| EA201201395A1 (ru) | Кнопочное устройство мундштука ингалятора сухого порошка | |
| CL2008000973A1 (es) | Compuestos derivados de 1-oxo-isoquinolina; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de enfermedades pulmonares obstructvas crónicas (epoc) y asma. | |
| NO20073909L (no) | Forstover-formulering | |
| EA201201393A1 (ru) | Ингалятор, разработанный для доставки лекарственного средства в виде сухого порошка | |
| EA201201389A1 (ru) | Ингалятор, создающий турбулентность | |
| MX2010012019A (es) | Producto farmaceutico que comprende un antagonista receptor muscarinico y un agonista de adrenoceptor beta2. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15I | Others concerning applications: loss of priority | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 7A, 8A, 9A E 10A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2536 DE 13-08-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |